No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
R-CVP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
R-CHOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
axicabtagene ciloleucel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
obinutuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
idelalisib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
duvelisib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
copanlisib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
cyclophosphamide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
chlorambucil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
ibritumomab tiuxetan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
G-CHOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
lisocabtagene maraleucel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
tisagenlecleucel-T
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
O-CVP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
zanubrutinib
Sensitive: B - Late Trials
|
MYD88 mutation
MYD88 mutation
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
ibrutinib
Sensitive: C3 – Early Trials
|
CARD11 mutation
CARD11 mutation
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
KMT2D mutation
KMT2D mutation
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
ibrutinib
Sensitive: C3 – Early Trials
|
TNFAIP3 mutation
TNFAIP3 mutation
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
ibrutinib
Sensitive: C3 – Early Trials
|
CD5 positive
CD5 positive
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
rituximab
Resistant: C3 – Early Trials
|
LDH elevation
LDH elevation
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
ViPOR
Sensitive: C3 – Early Trials
|
TP53 mutation + MET amplification + PD-L1 overexpression
TP53 mutation + MET amplification + PD-L1 overexpression
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
sintilimab
Sensitive: C4 – Case Studies
|
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
rituximab
Sensitive: C4 – Case Studies
|
BIRC3-MALT1 fusion
BIRC3-MALT1 fusion
|
Marginal Zone Lymphoma
Marginal Zone Lymphoma
|
R-CHOP
Sensitive: C4 – Case Studies
|
